Comparative Pharmacology
Head-to-head clinical analysis: KERLEDEX versus NAFAZAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERLEDEX versus NAFAZAIR.
KERLEDEX vs NAFAZAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
2.5 mg subcutaneously once daily.
None Documented
None Documented
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Category C
Category C
Corticosteroid/Antibiotic Combination
Intranasal Antihistamine/Corticosteroid